Notably, the HBsAg-positive group exhibited a decreased mutation frequency of CD79B, a key molecule of the BCR pathway; thus, HBV infection may affect the immune escape mechanism of tumor cells and, thus, the mutational selection of CD79B. Here, CD79B is linked to neoplasm.